A peptide vaccine targeting IDH1R132H (IDH1-vac) was proved safe and effective in stimulating immune response in a multi-center phase 1 trial (NOA-16 trial) in newly diagnosed glioma patients [111]. The gene discussed is IDH1; the disease is central nervous system cancer.